Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis*,**,*,★★
References (75)
The effect of cyclosporin on renal function
J Autoimmun
(1992)- et al.
Interaction of cyclosporine A and non-steroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis
Am J Med
(1992) - et al.
Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial
Lancet
(1999) - et al.
Toxicity of D-penicillamine in rheumatoid arthritis: a report of 63 patients including two with aplastic anemia and one with nephrotic syndrome
Am J Med
(1978) - et al.
Penicillamine-induced proteinuria: risk factors
Semin Arthritis Rheum
(1986) - et al.
Importance of ribonucleotide availability to proliferating T lymphocytes from healthy humans: disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
J Biol Chem
(1995) - et al.
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial
Lancet
(1999) - et al.
Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis
Arthritis Rheum
(1992) - et al.
Longterm therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
J Rheumatol
(1992) Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to non-steroidal anti-inflammatory drugs
Semin Nephrol
(1995)
The mechanism of action of FK-506 and cyclosporin A
Ann NY Acad Sci
Cyclosporin A treatment of refractory rheumatoid arthritis
Arthritis Rheum
Effects of cyclosporin on serum creatinine in patients with rheumatoid arthritis
Eur J Clin Pharmacol
Cyclosporin A in severe, treatment-refractory rheumatoid arthritis
Ann Intern Med
International Kidney Biopsy Registry of Cyclosporin (Sandimmune) in Autoimmune Diseases. Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients
Br J Rheumatol
Risk factor for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases
N Engl J Med
Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis
Clin Nephrol
Renal biopsy findings and follow-up of renal function in rheumatoid arthritis patients treated with cyclosporin A: an update form the International Kidney Biopsy Registry
Arthritis Rheum
Longterm, low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy
J Rheumatol
Cyclosporin in rheumatoid arthritis: a double blind, placebo-controlled study in 52 patients
Ann Rheum Dis
A study of the long-term efficacy and toxicity of cyclosporin A in rheumatoid arthritis
J Rheumatol
Cyclosporin in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis
J Rheumatol
Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine and placebo
Arthritis Rheum
US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis
J Rheumatol
Disease-modifying antirheumatic drugs: potential effects in older patients
Drugs Aging
Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis
J Hypertens
Gold nephropathy
Nephron
The natural course of gold nephropathy: a long-term study of 21 patients
Br Med J
The natural course of gold and penicillamine nephropathy: a longterm study of 54 patients
Adv Exp Med Biol
Membranous nephropathy in patients with rheumatoid arthritis: relationship to gold therapy
Medicine
Mild mesangial glomerulopathy: a frequent finding in patients with hematuria or proteinuria
Nephron
Long term chrysotherapy
Arthritis Rheum
Renal vein thrombosis associated with nephrotic syndrome and gold therapy in rheumatoid arthritis
South Med J
Gold nephropathy in juvenile rheumatoid arthritis
Am J Dis Child
Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients
Ann Rheum Dis
Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis
Br J Rheumatol
Auranofin therapy in rheumatoid arthritis
J Lab Clin Med
Cited by (0)
- *
Michael H. Schiff, MD: Professor of Clinical Medicine, University of Colorado School of Medicine, Denver, CO; Andrew Whelton, MD, DSc: Professor of Medicine Adjunct, Johns Hopkins University School of Medicine, Baltimore, MD.
- **
Dr. Schiff is a consultant for Amgen, Aventis Pharma, Bayer, Bristol-Myers Squibb, Centocor, Fujisawa, Genelabs, Hoffman-La Roche, Immunex, Eli Lilly, Merck, Neurobiological Tech, Inc., Novartis Pharmaceuticals, Parke-Davis, Pfizer Inc, Proctor & Gamble, Searle, SmithKline Beecham, and Wyeth-Ayerst.
- *
Dr. Whelton is a consultant for Aventis Pharma, Pfizer Inc., Pharmacia, and Searle.
- ★★
Address correspondence and reprint requests to Michael H. Schiff, MD, Denver Arthritis Clinic, 4545 East 9th St, Suite 510, Denver, CO 80220. E-mail: [email protected]